{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:13Z","timestamp":1794047413541,"version":"4.8.0"},"reference-count":48,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Apart from the central role of the activated JAK\/STAT signaling pathway, ASXL1 mutations are the most recurrent additional mutations in myeloproliferative neoplasms and occur much more commonly in myelofibrosis than in essential thrombocythemia and polycythemia vera. However, the mechanism of the association with ASXL1 mutations and bone marrow fibrosis remains unknown. Here, integrating our own data from patients with myeloproliferative neoplasms and a hematopoietic-specific Asxl1 deletion\/Jak2V617F mouse model, we show that ASXL1 mutations are associated with advanced myeloproliferative neoplasm phenotypes and onset of myelofibrosis. ASXL1 mutations induce skewed monocyte\/macrophage and neoplastic monocyte-derived fibrocyte differentiation, consequently they enhance inflammation and bone marrow fibrosis. Consistently, the loss of ASXL1 and JAK2V617F mutations in hematopoietic stem and progenitor cells leads to enhanced activation of polycomb group target genes, such as EGR1. The upregulation of EGR1, in turn, accounts for increased hematopoietic stem and progenitor cell commitment to the monocyte\/macrophage lineage. Moreover, EGR1 induces the activation of TNFA and thereby further drives the differentiation of monocytes to fibrocytes. Accordingly, combined treatment with a TNFR antagonist and ruxolitinib significantly reduces fibrocyte production in vitro. Altogether, these findings demonstrate that ASXL1 mutations accelerate fibrocyte production and inflammation in myeloproliferative neoplasms via the EGR1-TNFA axis, explaining the cellular and molecular basis for bone marrow fibrosis and the proof-ofconcept for anti-fibrosis treatment.<\/jats:p>","DOI":"10.3324\/haematol.2021.280320","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T02:51:51Z","timestamp":1661395911000},"page":"1359-1373","source":"Crossref","is-referenced-by-count":31,"title":["&lt;i&gt;ASXL1&lt;\/i&gt; mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms"],"prefix":"10.3324","volume":"108","author":[{"given":"Zhongxun","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiejun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqiang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zexing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiru","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"47582","doi-asserted-by":"crossref","unstructured":"Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. Blood. 2017; 130(23):2475-2483.","DOI":"10.1182\/blood-2017-06-782037"},{"key":"47583","doi-asserted-by":"crossref","unstructured":"Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021; 96(1):145-162.","DOI":"10.1002\/ajh.26050"},{"key":"47584","doi-asserted-by":"crossref","unstructured":"James C, Ugo V, Le Cou\u00e9dic JP. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-1148.","DOI":"10.1038\/nature03546"},{"key":"47585","doi-asserted-by":"crossref","unstructured":"Pikman Y, Lee BH, Mercher T. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006; 3(7):e270.","DOI":"10.1371\/journal.pmed.0030270"},{"key":"47586","doi-asserted-by":"crossref","unstructured":"Nangalia J, Massie CE, Baxter EJ. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25):2391-2405.","DOI":"10.1056\/NEJMoa1312542"},{"key":"47587","doi-asserted-by":"crossref","unstructured":"Tefferi A. Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms. N Engl J Med. 2012; 366(9):844-846.","DOI":"10.1056\/NEJMe1115119"},{"key":"47588","doi-asserted-by":"crossref","unstructured":"Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010; 115(17):3589-3597.","DOI":"10.1182\/blood-2009-04-215848"},{"key":"47589","doi-asserted-by":"crossref","unstructured":"Xing S, Wanting TH, Zhao W. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008; 111(10):5109-5117.","DOI":"10.1182\/blood-2007-05-091579"},{"key":"47590","doi-asserted-by":"crossref","unstructured":"Mullally A, Lane SW, Ball B. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010; 17(6):584-596.","DOI":"10.1016\/j.ccr.2010.05.015"},{"key":"47591","doi-asserted-by":"crossref","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013; 27(9):1861-1869.","DOI":"10.1038\/leu.2013.119"},{"key":"47592","doi-asserted-by":"crossref","unstructured":"Li B, Gale RP, Xu Z. Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis. J Hematol Oncol. 2017; 10(1):99.","DOI":"10.1186\/s13045-017-0472-5"},{"key":"47593","doi-asserted-by":"crossref","unstructured":"Yang Y, Akada H, Nath D, Hutchison RE, Mohi G. Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm. Blood. 2016; 127(26):3410-3423.","DOI":"10.1182\/blood-2015-11-679431"},{"key":"47594","doi-asserted-by":"crossref","unstructured":"Chen E, Schneider RK, Breyfogle LJ. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood. 2015; 125(2):327-335.","DOI":"10.1182\/blood-2014-04-567024"},{"key":"47595","doi-asserted-by":"crossref","unstructured":"Jacquelin S, Straube J, Cooper L. Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation. Blood. 2018; 132(26):2707-2721.","DOI":"10.1182\/blood-2018-04-846220"},{"key":"47596","doi-asserted-by":"crossref","unstructured":"Simon J, Chiang A, Bender W. Ten different Polycomb group genes are required for spatial control of the abdA and AbdB homeotic products. Development. 1992; 114(2):493-505.","DOI":"10.1242\/dev.114.2.493"},{"key":"47597","doi-asserted-by":"crossref","unstructured":"Dey A, Seshasayee D, Noubade R. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science. 2012; 337(6101):1541-1546.","DOI":"10.1126\/science.1221711"},{"key":"47598","doi-asserted-by":"crossref","unstructured":"Wu X, Bekker-Jensen IH, Christensen J. Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals. Cell Res. 2015; 25(11):1205-1218.","DOI":"10.1038\/cr.2015.121"},{"key":"47599","doi-asserted-by":"crossref","unstructured":"Abdel-Wahab O, Adli M, Lafave LM. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell. 2012; 22(2):180-193.","DOI":"10.1016\/j.ccr.2012.06.032"},{"key":"47600","doi-asserted-by":"crossref","unstructured":"Abdel-Wahab O, Gao J, Adli M. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med. 2013; 210(12):2641-2659.","DOI":"10.1084\/jem.20131141"},{"key":"47601","doi-asserted-by":"crossref","unstructured":"Guo Y, Zhou Y, Yamatomo S. ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis. Leukemia. 2019; 33(5):1287-1291.","DOI":"10.1038\/s41375-018-0347-y"},{"key":"47602","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-2405.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"47603","doi-asserted-by":"crossref","unstructured":"Ozono Y, Shide K, Kameda T. Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice. Leukemia. 2021; 35(2):454-467.","DOI":"10.1038\/s41375-020-0880-3"},{"key":"47604","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Manshouri T, Pilling D. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med. 2016; 213(9):1723-1740.","DOI":"10.1084\/jem.20160283"},{"key":"47605","doi-asserted-by":"crossref","unstructured":"Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011; 29(10):1356-1363.","DOI":"10.1200\/JCO.2010.32.9490"},{"key":"47606","doi-asserted-by":"crossref","unstructured":"Koschmieder S, Chatain N. Role of inflammation in the biology of myeloproliferative neoplasms. Blood Rev. 2020; 42:100711.","DOI":"10.1016\/j.blre.2020.100711"},{"key":"47607","doi-asserted-by":"crossref","unstructured":"Heaton WL, Senina AV, Pomicter AD. Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion. Leukemia. 2018; 32(11):2399-2411.","DOI":"10.1038\/s41375-018-0131-z"},{"key":"47608","doi-asserted-by":"crossref","unstructured":"Fisher DAC, Miner CA, Engle EK. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NF\u03baB signaling. Leukemia. 2019; 33(8):1978-1995.","DOI":"10.1038\/s41375-019-0379-y"},{"key":"47609","doi-asserted-by":"crossref","unstructured":"Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol. 2009; 27:669-692.","DOI":"10.1146\/annurev.immunol.021908.132557"},{"key":"47610","doi-asserted-by":"crossref","unstructured":"Dom\u00ednguez PM, Ardav\u00edn C. Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation. Immunol Rev. 2010; 234(1):90-104.","DOI":"10.1111\/j.0105-2896.2009.00876.x"},{"key":"47611","doi-asserted-by":"crossref","unstructured":"Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol. 2020; 15:123-147.","DOI":"10.1146\/annurev-pathmechdis-012418-012718"},{"key":"47612","doi-asserted-by":"crossref","unstructured":"Chow A, Lucas D, Hidalgo A. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp Med. 2011; 208(2):261-271.","DOI":"10.1084\/jem.20101688"},{"key":"47613","doi-asserted-by":"crossref","unstructured":"Schneider RK, Mullally A, Dugourd A. Gli1(+) mesenchymal stromal cells are a key driver of bone marrow fibrosis and an important cellular therapeutic target. Cell Stem Cell. 2017; 20(6):785-800.","DOI":"10.1016\/j.stem.2017.03.008"},{"key":"47614","doi-asserted-by":"crossref","unstructured":"Decker M, Martinez-Morentin L, Wang G. Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis. Nat Cell Biol. 2017; 19(6):677-688.","DOI":"10.1038\/ncb3530"},{"key":"47615","doi-asserted-by":"crossref","unstructured":"Gleitz HFE, Dugourd AJF, Leimk\u00fchler NB. Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN. Blood. 2020; 136(18):2051-2064.","DOI":"10.1182\/blood.2019004095"},{"key":"47616","doi-asserted-by":"crossref","unstructured":"Asada S, Fujino T, Goyama S, Kitamura T. The role of ASXL1 in hematopoiesis and myeloid malignancies. Cell Mol Life Sci. 2019; 76(13):2511-2523.","DOI":"10.1007\/s00018-019-03084-7"},{"key":"47617","doi-asserted-by":"crossref","unstructured":"Scheuermann JC, de Ayala Alonso AG, Oktaba K. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature. 2010; 465(7295):243-247.","DOI":"10.1038\/nature08966"},{"key":"47618","doi-asserted-by":"crossref","unstructured":"Krishnaraju K, Hoffman B, Liebermann DA. Early growth response gene 1 stimulates development of hematopoietic progenitor cells along the macrophage lineage at the expense of the granulocyte and erythroid lineages. Blood. 2001; 97(5):1298-1305.","DOI":"10.1182\/blood.V97.5.1298"},{"key":"47619","doi-asserted-by":"crossref","unstructured":"Yao J, Mackman N, Edgington TS, Fan ST. Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors. J Biol Chem. 1997; 272(28):17795-17801.","DOI":"10.1074\/jbc.272.28.17795"},{"key":"47620","doi-asserted-by":"crossref","unstructured":"Fleischman AG, Aichberger KJ, Luty SB. TNFa facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011; 118(24):6392-6398.","DOI":"10.1182\/blood-2011-04-348144"},{"key":"47621","doi-asserted-by":"crossref","unstructured":"Leimk\u00fchler NB, Gleitz HFE, Ronghui L. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell. 2021; 28(4):637-652.","DOI":"10.1016\/j.stem.2020.11.004"},{"key":"47622","doi-asserted-by":"crossref","unstructured":"Yang H, Kurtenbach S, Guo Y. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies. Blood. 2018; 131(3):328-341.","DOI":"10.1182\/blood-2017-06-789669"},{"key":"47623","doi-asserted-by":"crossref","unstructured":"Balasubramani A, Larjo A, Bassein JA. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex. Nat Commun. 2015; 6:7307.","DOI":"10.1038\/ncomms8307"},{"key":"47624","doi-asserted-by":"crossref","unstructured":"Koschmieder S, Mughal TI, Hasselbalch HC. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia. 2016; 30(5):1018-1024.","DOI":"10.1038\/leu.2016.12"},{"key":"47625","doi-asserted-by":"crossref","unstructured":"Zingariello M, Martelli F, Ciaffoni F. Characterization of the TGF-b1 signaling abnormalities in the Gata1low mouse model of myelofibrosis. Blood. 2013; 121(17):3345-3363.","DOI":"10.1182\/blood-2012-06-439661"},{"key":"47626","doi-asserted-by":"crossref","unstructured":"Kisseleva T, Uchinami H, Feirt N. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol. 2006; 45(3):429-438.","DOI":"10.1016\/j.jhep.2006.04.014"},{"key":"47627","doi-asserted-by":"crossref","unstructured":"Reich B, Schmidbauer K, Rodriguez Gomez M. Fibrocytes develop outside the kidney but contribute to renal fibrosis in a mouse model. Kidney Int. 2013; 84(1):78-89.","DOI":"10.1038\/ki.2013.84"},{"key":"47628","doi-asserted-by":"crossref","unstructured":"Fursova NA, Turberfield AH, Blackledge NP. BAP1 constrains pervasive H2AK119ub1 to control the transcriptional potential of the genome. Genes Dev. 2021; 35(9-10):749-770.","DOI":"10.1101\/gad.347005.120"},{"key":"47629","doi-asserted-by":"crossref","unstructured":"Conway E, Rossi F, Fernandez-Perez D. BAP1 enhances Polycomb repression by counteracting widespread H2AK119ub1 deposition and chromatin condensation. Mol Cell. 2021; 81(17):3526-3541.","DOI":"10.1016\/j.molcel.2021.06.020"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.280320\/74796","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.280320\/75575","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10780\/74796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:02:14Z","timestamp":1794045734000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.280320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.280320","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,25]]}}}